SOURCE: Crucell N.V.

October 31, 2006 08:19 ET

Crucell to Release Q3 2006 Results on Tuesday, November 14, 2006

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- October 31, 2006 -- Leiden, The Netherlands, October 31, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that it will release its financial results for the third quarter of 2006 on Tuesday, November 14, 2006 at 08:00 Central European Time (CET) (02:00 US Eastern Daylight Time).

At 14:00 CET, Crucell will conduct a conference call open to all which will also be webcast. To participate in the conference call, please call one of the following numbers 10 minutes prior to commencement:

       888-408-5406 (toll-free) or 480-293-1748 for the US;
   0800-358-5255 (toll-free) or +44-20-7190-1492 for the UK; and
 0800-265-8531 (toll free) or +31 20 794 8505 for The Netherlands.

Following a presentation of the results you will be able to ask questions during a question and answer session.

The live audio webcast can be accessed via the homepage of Crucell's website at www.crucell.com, and will be archived and available for replay following the event.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Korea and the US. The Company employs about 900 people. For more information, please visit www.crucell.com.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20- F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

For further information please contact:

Crucell N.V.                            For Crucell N.V. in the USA:
Paul Vermeij                            Redington Inc.
Director Investor Relations and         Thomas Redington
Corporate Communications                Tel. +1 212-926-1733
Tel. +31 (0)71 524 8718                 tredington@redingtoninc.com
p.vermeij@crucell.com                      





Copyright © Hugin ASA 2006. All rights reserved.

Contact Information